EP1668024A4
(en )
2008-07-02
Oligonucleotide compositions and methods for treating disease including inflammatory conditions
IL178730A0
(en )
2007-03-08
New pharmaceutical compositions for the treatment of sexual disorders ii
IL152127A0
(en )
2003-05-29
Probiotic compositions for the treatment of inflammatory bowel disease
IL189611A0
(en )
2008-06-05
Treatment of inflammatory bowel disease
HK1107026A1
(en )
2008-03-28
Treatment of short bowel syndrome patients with colon-in-continuity
IL178827A0
(en )
2007-03-08
Use of reboxetine for the treatment of pain
EP1827459A4
(en )
2010-01-13
Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease
EP1954800A4
(en )
2010-03-03
Composition and use of phyto-percolate for treatment of disease
GB0320238D0
(en )
2003-10-01
Treatment of disease
EP1755635A4
(en )
2011-04-06
Treatment of inflammatory airway disease
EP1928247A4
(en )
2009-10-28
Composition and use of phyto-percolate for treatment of disease
EP1815867A4
(en )
2010-06-09
Combination drug for treating autoimmune disease
EP1768656A4
(en )
2008-01-23
Treatment for ocular disease
ZA200704684B
(en )
2008-09-25
Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease
EP2044957A4
(en )
2011-01-05
Treatment agent for inflammatory bowel disease
GB0526394D0
(en )
2006-02-08
Treatment of inflammatory diseases
GB0400802D0
(en )
2004-02-18
Compounds for the treatment of disease
EP1806137A4
(en )
2011-03-30
Therapeutic agent for glomerular disease
IL186286A0
(en )
2008-01-20
Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
EP1876175A4
(en )
2012-06-27
Therapeutic agent for corneal disease
TWI315984B
(en )
2009-10-21
Agent for treatment of anal disease
GB0425854D0
(en )
2004-12-29
Therapeutic treatment
ZA200607463B
(en )
2008-10-29
New pharmaceutical compositions for the treatment of sexual disorders II
GB0623740D0
(en )
2007-01-10
Treatment of disease
IL183926A0
(en )
2007-10-31
PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-kB ACTIVITY